PhytoMedical To Develop New Class Of Antitumour Agents Designed To Bind To DNA And Kill Cancer Cells.

Patented Technology Blocks Cancer Cell DNA Replication Through Process Called "bis-intercalation" Which Inhibits Cancer Cell Growth

PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced the signing of their first developmental collaboration in the area of cancer research with the renowned Dartmouth College.

Led by Dr. Gordon W. Gribble, Dartmouth scientists have synthesized a novel class of antitumour agents with a cytotoxic affinity for cancer cells that are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

In Dr. Gribble's initial published research his synthesized compounds were evaluated on their ability to bind to DNA and measured for cytotoxicity against a mouse leukemia cell line. A patent was issued based on the success of the research and the promise that these novel compounds have for the control of cancer.

Given the ongoing problem of cancer chemotherapeutic drug resistance, it is essential to develop new drugs with new and more powerful modes of action. In collaboration with Dr. Gribble and Dartmouth College, PhytoMedical plans to improve upon the concept of bis-intercalation and will evaluate these new compounds against several different cancer cell lines, including prostate, lung, brain and bladder cancer.

"Our cancer research collaboration with Dartmouth College adds yet another novel class of compounds to our expanding drug discovery pipeline," commented PhytoMedical President and CEO, Mr. Greg Wujek.

"In addition to today's new cancer research initiative, we also continue with the development of an entirely new, innovative class of polyphenolic compounds shown in published human and pre-clinical animal studies to favorably effect type-2 diabetes. In fact, participants in the human study had their blood sugar levels drop by an average of 18 to 29% - without side effects."

Dr. Gordon W. Gribble

Dr. Gordon W. Gribble received his B.S. degree in Chemistry in 1963 from the University of California, Berkeley, and his Ph.D. in Organic Chemistry in 1967 from the University of Oregon. He has published 290 papers and review articles in the field of organic chemistry, focusing on the synthesis of biologically active natural products, new synthetic methodology, heterocyclic organic chemistry, chemopreventive triterpenoids and the isolation of natural products from marine and terrestrial sources. He has also refereed 180 research proposals for 17 agencies.

Additionally, Dr. Gribble has garnered numerous awards, including the National Institutes of Health Research Career Development Award, three Dartmouth Senior Faculty Fellowships, the National Science Foundation Professional Development Award and the American Cyanamid Academic Award. In 1998, he was awarded the Chemistry Alumni Award by the University of Oregon. In 2005, he was named to an endowed Chair at Dartmouth.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit

http://www.phytomedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:

http://www.PhytoMedical.com/IR/PressReleases/20070605-1.html

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.